AroCell AB (publ)
STO:AROC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AroCell AB (publ)
STO:AROC
|
SE |
AroCell AB (publ)
AroCell AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2011-05-25. The firm's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
AroCell AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2011-05-25. The firm's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
